Abstract 18472: Enhancing the Therapeutic Potential of Induced Pluripotent Stem Cell Derived Cardiomyocytes Through Targeting the Hippo Signalling Pathway

Abstract 18472: Enhancing the Therapeutic Potential of Induced Pluripotent Stem Cell Derived Cardiomyocytes Through Targeting the Hippo Signalling Pathway

Cell based therapy using stem cell derived cardiomyocytes, has emerged as a potential therapeutic approach for cardiac diseases such as myocardial infarction and heart failure. Induced pluripotent stem cells (iPSC) could be an ideal source of cardiomyocytes (iPS-CM). However, challenges facing this...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 2016-11, Vol.134 (Suppl_1 Suppl 1), p.A18472-A18472
Hauptverfasser: Robertson, Abigail C, Mohammed, Tamer, Zi, Min, Prehar, Sukhpal, Stafford, Nicholas, Cartwright, Elizabeth J, Oceandy, Delvac
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A18472
container_issue Suppl_1 Suppl 1
container_start_page A18472
container_title Circulation (New York, N.Y.)
container_volume 134
creator Robertson, Abigail C
Mohammed, Tamer
Zi, Min
Prehar, Sukhpal
Stafford, Nicholas
Cartwright, Elizabeth J
Oceandy, Delvac
description Cell based therapy using stem cell derived cardiomyocytes, has emerged as a potential therapeutic approach for cardiac diseases such as myocardial infarction and heart failure. Induced pluripotent stem cells (iPSC) could be an ideal source of cardiomyocytes (iPS-CM). However, challenges facing this approach include the high number of viable cells needed to survive in pathological conditions. The Hippo signalling pathway is a key pathway involved in regulating cardiomyocyte proliferation and survival in both embryonic and adult hearts. In this study, we target the Hippo pathway to enhance the therapeutic potential of iPS-CM.Skin fibroblasts were reprogrammed to iPSC and then differentiated to cardiomyocytes. The Hippo pathway was modified by genetic ablation of Mst1, a major upstream regulator of the Hippo pathway, or by overexpressing YAP, the main downstream effector of the pathway. We found that genetic ablation of Mst1 leads to significantly increased reprogramming efficiency by 43.8±2.4%. iPSC lacking MST1 displayed increase proliferation (12±1.5% P
format Article
fullrecord <record><control><sourceid>wolterskluwer</sourceid><recordid>TN_cdi_wolterskluwer_health_00003017-201611111-02725</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>00003017-201611111-02725</sourcerecordid><originalsourceid>FETCH-wolterskluwer_health_00003017-201611111-027253</originalsourceid><addsrcrecordid>eNqdT1tOwzAQtBBIhMcd9gKRHCdpKH8oFJW_Ss1_tSTb2ODakb0hylU4LSmCCzA_o53RzGouRJKVqkiLMl9fikRKuU6rXKlrcRPj-3Ku8qpMxNfTW-SALUP2UFTqETZOo2uN64E1QaMp4EAjmxZ2nsmxQQv-CK-uG1vqYGfHYIYfB_ZMJ6jJWnimYD4Xt8bQGX-afTszxaUt-LHX0GDoif9-bM0weNib3qG1Z3GHrCec78TVEW2k-1--FcXLpqm36eQtU4gfdpwoHDShZX1YFslcZlWqZLbKzkilqlSZ_zP2DZREYp8</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Abstract 18472: Enhancing the Therapeutic Potential of Induced Pluripotent Stem Cell Derived Cardiomyocytes Through Targeting the Hippo Signalling Pathway</title><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Robertson, Abigail C ; Mohammed, Tamer ; Zi, Min ; Prehar, Sukhpal ; Stafford, Nicholas ; Cartwright, Elizabeth J ; Oceandy, Delvac</creator><creatorcontrib>Robertson, Abigail C ; Mohammed, Tamer ; Zi, Min ; Prehar, Sukhpal ; Stafford, Nicholas ; Cartwright, Elizabeth J ; Oceandy, Delvac</creatorcontrib><description>Cell based therapy using stem cell derived cardiomyocytes, has emerged as a potential therapeutic approach for cardiac diseases such as myocardial infarction and heart failure. Induced pluripotent stem cells (iPSC) could be an ideal source of cardiomyocytes (iPS-CM). However, challenges facing this approach include the high number of viable cells needed to survive in pathological conditions. The Hippo signalling pathway is a key pathway involved in regulating cardiomyocyte proliferation and survival in both embryonic and adult hearts. In this study, we target the Hippo pathway to enhance the therapeutic potential of iPS-CM.Skin fibroblasts were reprogrammed to iPSC and then differentiated to cardiomyocytes. The Hippo pathway was modified by genetic ablation of Mst1, a major upstream regulator of the Hippo pathway, or by overexpressing YAP, the main downstream effector of the pathway. We found that genetic ablation of Mst1 leads to significantly increased reprogramming efficiency by 43.8±2.4%. iPSC lacking MST1 displayed increase proliferation (12±1.5% P&lt;0.001), survival and viability (20±4.3% P&lt;0.001) in both normal and hypoxic conditions compared to controls. In addition, overexpression of wild type and the constitutively active form of YAP (S127A) increased cell proliferation in iPS-CM compared to control iPS-CM as shown with an EdU assay (+20.8±1.6% P&lt;0.01) and Ki67 staining (4.9±0.9% P&lt;0.001). Overexpression of YAP leads to up regulation of genes associated with inhibition of apoptosis and promotion of cell proliferation. Preliminary studies show that mouse iPS-CM with overexpression of YAP (S127A) are retained in the myocardium following intracardiac injection and does not cause any adverse effects as confirmed by histological, echocardiography and electrocardiogram analyses. In conclusion, targeting the Hippo pathway in iPSC and iPS-CM significantly increases proliferation and survival in both normal and hypoxic conditions. Therefore, modulation of the Hippo pathway could become a new strategy to enhance the therapeutic potential of iPS-CM.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><language>eng</language><publisher>by the American College of Cardiology Foundation and the American Heart Association, Inc</publisher><ispartof>Circulation (New York, N.Y.), 2016-11, Vol.134 (Suppl_1 Suppl 1), p.A18472-A18472</ispartof><rights>2016 by the American College of Cardiology Foundation and the American Heart Association, Inc.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Robertson, Abigail C</creatorcontrib><creatorcontrib>Mohammed, Tamer</creatorcontrib><creatorcontrib>Zi, Min</creatorcontrib><creatorcontrib>Prehar, Sukhpal</creatorcontrib><creatorcontrib>Stafford, Nicholas</creatorcontrib><creatorcontrib>Cartwright, Elizabeth J</creatorcontrib><creatorcontrib>Oceandy, Delvac</creatorcontrib><title>Abstract 18472: Enhancing the Therapeutic Potential of Induced Pluripotent Stem Cell Derived Cardiomyocytes Through Targeting the Hippo Signalling Pathway</title><title>Circulation (New York, N.Y.)</title><description>Cell based therapy using stem cell derived cardiomyocytes, has emerged as a potential therapeutic approach for cardiac diseases such as myocardial infarction and heart failure. Induced pluripotent stem cells (iPSC) could be an ideal source of cardiomyocytes (iPS-CM). However, challenges facing this approach include the high number of viable cells needed to survive in pathological conditions. The Hippo signalling pathway is a key pathway involved in regulating cardiomyocyte proliferation and survival in both embryonic and adult hearts. In this study, we target the Hippo pathway to enhance the therapeutic potential of iPS-CM.Skin fibroblasts were reprogrammed to iPSC and then differentiated to cardiomyocytes. The Hippo pathway was modified by genetic ablation of Mst1, a major upstream regulator of the Hippo pathway, or by overexpressing YAP, the main downstream effector of the pathway. We found that genetic ablation of Mst1 leads to significantly increased reprogramming efficiency by 43.8±2.4%. iPSC lacking MST1 displayed increase proliferation (12±1.5% P&lt;0.001), survival and viability (20±4.3% P&lt;0.001) in both normal and hypoxic conditions compared to controls. In addition, overexpression of wild type and the constitutively active form of YAP (S127A) increased cell proliferation in iPS-CM compared to control iPS-CM as shown with an EdU assay (+20.8±1.6% P&lt;0.01) and Ki67 staining (4.9±0.9% P&lt;0.001). Overexpression of YAP leads to up regulation of genes associated with inhibition of apoptosis and promotion of cell proliferation. Preliminary studies show that mouse iPS-CM with overexpression of YAP (S127A) are retained in the myocardium following intracardiac injection and does not cause any adverse effects as confirmed by histological, echocardiography and electrocardiogram analyses. In conclusion, targeting the Hippo pathway in iPSC and iPS-CM significantly increases proliferation and survival in both normal and hypoxic conditions. Therefore, modulation of the Hippo pathway could become a new strategy to enhance the therapeutic potential of iPS-CM.</description><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqdT1tOwzAQtBBIhMcd9gKRHCdpKH8oFJW_Ss1_tSTb2ODakb0hylU4LSmCCzA_o53RzGouRJKVqkiLMl9fikRKuU6rXKlrcRPj-3Ku8qpMxNfTW-SALUP2UFTqETZOo2uN64E1QaMp4EAjmxZ2nsmxQQv-CK-uG1vqYGfHYIYfB_ZMJ6jJWnimYD4Xt8bQGX-afTszxaUt-LHX0GDoif9-bM0weNib3qG1Z3GHrCec78TVEW2k-1--FcXLpqm36eQtU4gfdpwoHDShZX1YFslcZlWqZLbKzkilqlSZ_zP2DZREYp8</recordid><startdate>20161111</startdate><enddate>20161111</enddate><creator>Robertson, Abigail C</creator><creator>Mohammed, Tamer</creator><creator>Zi, Min</creator><creator>Prehar, Sukhpal</creator><creator>Stafford, Nicholas</creator><creator>Cartwright, Elizabeth J</creator><creator>Oceandy, Delvac</creator><general>by the American College of Cardiology Foundation and the American Heart Association, Inc</general><scope/></search><sort><creationdate>20161111</creationdate><title>Abstract 18472: Enhancing the Therapeutic Potential of Induced Pluripotent Stem Cell Derived Cardiomyocytes Through Targeting the Hippo Signalling Pathway</title><author>Robertson, Abigail C ; Mohammed, Tamer ; Zi, Min ; Prehar, Sukhpal ; Stafford, Nicholas ; Cartwright, Elizabeth J ; Oceandy, Delvac</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-wolterskluwer_health_00003017-201611111-027253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Robertson, Abigail C</creatorcontrib><creatorcontrib>Mohammed, Tamer</creatorcontrib><creatorcontrib>Zi, Min</creatorcontrib><creatorcontrib>Prehar, Sukhpal</creatorcontrib><creatorcontrib>Stafford, Nicholas</creatorcontrib><creatorcontrib>Cartwright, Elizabeth J</creatorcontrib><creatorcontrib>Oceandy, Delvac</creatorcontrib><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Robertson, Abigail C</au><au>Mohammed, Tamer</au><au>Zi, Min</au><au>Prehar, Sukhpal</au><au>Stafford, Nicholas</au><au>Cartwright, Elizabeth J</au><au>Oceandy, Delvac</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abstract 18472: Enhancing the Therapeutic Potential of Induced Pluripotent Stem Cell Derived Cardiomyocytes Through Targeting the Hippo Signalling Pathway</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><date>2016-11-11</date><risdate>2016</risdate><volume>134</volume><issue>Suppl_1 Suppl 1</issue><spage>A18472</spage><epage>A18472</epage><pages>A18472-A18472</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><abstract>Cell based therapy using stem cell derived cardiomyocytes, has emerged as a potential therapeutic approach for cardiac diseases such as myocardial infarction and heart failure. Induced pluripotent stem cells (iPSC) could be an ideal source of cardiomyocytes (iPS-CM). However, challenges facing this approach include the high number of viable cells needed to survive in pathological conditions. The Hippo signalling pathway is a key pathway involved in regulating cardiomyocyte proliferation and survival in both embryonic and adult hearts. In this study, we target the Hippo pathway to enhance the therapeutic potential of iPS-CM.Skin fibroblasts were reprogrammed to iPSC and then differentiated to cardiomyocytes. The Hippo pathway was modified by genetic ablation of Mst1, a major upstream regulator of the Hippo pathway, or by overexpressing YAP, the main downstream effector of the pathway. We found that genetic ablation of Mst1 leads to significantly increased reprogramming efficiency by 43.8±2.4%. iPSC lacking MST1 displayed increase proliferation (12±1.5% P&lt;0.001), survival and viability (20±4.3% P&lt;0.001) in both normal and hypoxic conditions compared to controls. In addition, overexpression of wild type and the constitutively active form of YAP (S127A) increased cell proliferation in iPS-CM compared to control iPS-CM as shown with an EdU assay (+20.8±1.6% P&lt;0.01) and Ki67 staining (4.9±0.9% P&lt;0.001). Overexpression of YAP leads to up regulation of genes associated with inhibition of apoptosis and promotion of cell proliferation. Preliminary studies show that mouse iPS-CM with overexpression of YAP (S127A) are retained in the myocardium following intracardiac injection and does not cause any adverse effects as confirmed by histological, echocardiography and electrocardiogram analyses. In conclusion, targeting the Hippo pathway in iPSC and iPS-CM significantly increases proliferation and survival in both normal and hypoxic conditions. Therefore, modulation of the Hippo pathway could become a new strategy to enhance the therapeutic potential of iPS-CM.</abstract><pub>by the American College of Cardiology Foundation and the American Heart Association, Inc</pub></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 2016-11, Vol.134 (Suppl_1 Suppl 1), p.A18472-A18472
issn 0009-7322
1524-4539
language eng
recordid cdi_wolterskluwer_health_00003017-201611111-02725
source American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete
title Abstract 18472: Enhancing the Therapeutic Potential of Induced Pluripotent Stem Cell Derived Cardiomyocytes Through Targeting the Hippo Signalling Pathway
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T20%3A37%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wolterskluwer&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abstract%2018472:%20Enhancing%20the%20Therapeutic%20Potential%20of%20Induced%20Pluripotent%20Stem%20Cell%20Derived%20Cardiomyocytes%20Through%20Targeting%20the%20Hippo%20Signalling%20Pathway&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=Robertson,%20Abigail%20C&rft.date=2016-11-11&rft.volume=134&rft.issue=Suppl_1%20Suppl%201&rft.spage=A18472&rft.epage=A18472&rft.pages=A18472-A18472&rft.issn=0009-7322&rft.eissn=1524-4539&rft_id=info:doi/&rft_dat=%3Cwolterskluwer%3E00003017-201611111-02725%3C/wolterskluwer%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true